Ivan Kairatov is a Biopharma expert with deep knowledge of tech and innovation in the industry and experience in research and development. Today, we are discussing Med-Life Discoveries (MLD), their mission, and the promising results of their Phase I study on PPI-1011, a synthetic plasmalogen
Clinical trials have long been criticized for their lack of diversity, particularly in the participation of women. Historically, such exclusions have led to significant gaps in medical knowledge and treatment efficacy across genders, resulting in potentially biased outcomes for a substantial
Imagine a mother in a remote African village, anxiously awaiting crucial medication for her ailing child, which arrives via drone while a diagnosis is performed using an AI-powered app. This scenario, once mere science fiction, will increasingly become reality thanks to the transformative
CT scans, while critical in diagnosing a myriad of medical conditions, have raised significant concerns due to the high radiation exposure patients experience. The issue is exacerbated by the inconsistent radiation dosages administered across various healthcare facilities, leading to potential
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. In this interview, Ivan sheds light on the role of AI in healthcare cybersecurity, highlighting the benefits, adoption rates, future prospects, and the
The dawn of holography technology marks a revolutionary period in healthcare, enhancing diagnostic capabilities, surgical planning, and medical education. With predictions of the global medical holography market reaching $7.11 billion by 2029, the healthcare sector stands on the brink of profound
Ivan Kairatov is a Biopharma expert, with deep knowledge in tech and innovation in the industry and experience in research and development. Today, we will discuss the intricacies of protein kinase research, the role of AI in predicting interactions, and the development of KinasePred. Can you
On March 3, 2025, Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focusing on targeting the CLEVER-1 receptor to reprogram myeloid cells for anti-tumor immunity in both hematological and solid tumors, announced a significant milestone. Their lead therapeutic candidate,
The pharmaceutical industry is abuzz with excitement over a new class of cancer drugs known as PD-1/VEGF inhibitors. These promising therapies, currently undergoing clinical trials, might leapfrog Merck & Co.’s highly successful cancer immunotherapy, Keytruda. The advent of these new drugs could
Parkinson's disease, a devastating neurodegenerative disorder, is characterized by the relentless loss of dopaminergic neurons, which leads to significant motor dysfunction and a decline in overall quality of life. Central to the pathology of PD are aggregates of alpha-synuclein protein and
